Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01914484
Title Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto|Novartis

chronic myeloid leukemia


Nilotinib + Ruxolitinib

Age Groups: adult
Covered Countries CAN

No variant requirements are available.